{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:58:09Z","timestamp":1775059089031,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen GmbH Germany","award":["AIO-SUP-0116"],"award-info":[{"award-number":["AIO-SUP-0116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00520-019-05018-2","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T04:19:36Z","timestamp":1565756376000},"page":"2175-2184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany"],"prefix":"10.1007","volume":"28","author":[{"name":"for the Associations Supportive Care in Oncology (AGSMO), Medical Oncology (AIO), Urological Oncology (AUO), within the German Cancer Society (DKG) and the German Osteooncological Society (DOG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-0265","authenticated-orcid":false,"given":"Hartmut","family":"Link","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Diel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten-H.","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Holtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kerkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"issue":"8 Suppl","key":"5018_CR1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer. 80(8 Suppl):1588\u20131594","journal-title":"Cancer."},{"issue":"2","key":"5018_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129(2):495\u2013503","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5018_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184(1):162\u2013167","journal-title":"J Urol"},{"issue":"9","key":"5018_CR4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.18553\/jmcp.2010.16.9.693","volume":"16","author":"A Barlev","year":"2010","unstructured":"Barlev A, Song X, Ivanov B, Setty V, Chung K (2010) Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 16(9):693\u2013702","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"5018_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","volume":"26","author":"C Yong","year":"2014","unstructured":"Yong C, Onukwugha E, Mullins CD (2014) Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol 26(3):274\u2013283","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"5018_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3111\/13696998.2016.1150852","volume":"19","author":"J Pereira","year":"2016","unstructured":"Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R (2016) Cost of skeletal complications from bone metastases in six European countries. J Med Econ 19(6):611\u2013618","journal-title":"J Med Econ"},{"key":"5018_CR7","unstructured":"Supportive Therapie bei onkologischen PatientInnen - Langversion 1.0, 2016, AWMF Registernummer: 032\/054OL2016 18.4.2019 30.12.2017]. Available from: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/supportive-therapie\/ . Accessed 4 Dec 2018"},{"issue":"Suppl 3","key":"5018_CR8","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, Group EGW (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 25(Suppl 3):iii124\u2013iii137","journal-title":"Ann Oncol"},{"key":"5018_CR9","unstructured":"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, diagnose und Therapie der verschiedenen Stadien des Prostatakarzinom. Berlin 2018 4\/2019]. Available from: http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/ . Accessed 4 Dec 2018"},{"issue":"3\u20134","key":"5018_CR10","first-page":"81","volume":"9","author":"H Miriam","year":"2017","unstructured":"Miriam H, Jens B, Arnulf S, Tilman T (2017) Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol 9(3\u20134):81\u201388","journal-title":"Ther Adv Urol"},{"issue":"5","key":"5018_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/M16-2577","volume":"167","author":"SMH Alibhai","year":"2017","unstructured":"Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Tomlinson GA, Winquist E (2017) Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis. Ann Intern Med 167(5):341\u2013350","journal-title":"Ann Intern Med"},{"issue":"6","key":"5018_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339(6):357\u2013363","journal-title":"N Engl J Med"},{"issue":"12","key":"5018_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","volume":"19","author":"IJ Diel","year":"2008","unstructured":"Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19(12):2007\u20132011","journal-title":"Ann Oncol"},{"issue":"1","key":"5018_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00520-015-2779-5","volume":"24","author":"H Link","year":"2016","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P (2016) Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy - a representative sample survey in Germany. Support Care Cancer 24(1):367\u2013376","journal-title":"Support Care Cancer"},{"issue":"1","key":"5018_CR15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57(1):289\u2013300","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"5018_CR16","first-page":"567","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988. xxi) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, Hillsdale, p 567","edition":"2"},{"key":"5018_CR17","volume-title":"Classification and regression trees","author":"L Breiman","year":"1984","unstructured":"Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Chapman and Hall, New York"},{"issue":"3","key":"5018_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1214\/ss\/1009213726","volume":"16","author":"L Breiman","year":"2001","unstructured":"Breiman L (2001) Statistical modeling: the two cultures (with comments and a rejoinder by the author). Stat Sci 16(3):199\u2013231","journal-title":"Stat Sci"},{"issue":"4","key":"5018_CR19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00520-018-4481-x","volume":"27","author":"Hartmut Link","year":"2018","unstructured":"Link H, Kerkmann M, Holtmann L, Ortner P (2019) G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27(4):1459","journal-title":"Supportive Care in Cancer"},{"key":"5018_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/bonekey.2015.60","volume":"4","author":"P Hadji","year":"2015","unstructured":"Hadji P (2015) Cancer treatment-induced bone loss in women with breast cancer. BoneKEy Rep 4:692","journal-title":"BoneKEy Rep"},{"issue":"1","key":"5018_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O\u2019Connor T, Velasco MR Jr, Weckstein D, O\u2019Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 317(1):48\u201358","journal-title":"JAMA."},{"issue":"4","key":"5018_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00520-018-4060-1","volume":"26","author":"A Menshawy","year":"2018","unstructured":"Menshawy A, Mattar O, Abdulkarim A, Kasem S, Nasreldin N, Menshawy E, Mohammed S, Abdel-Maboud M, Gadelkarim M, el Ashal GG, Elgebaly AS (2018) Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 26(4):1029\u20131038","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05018-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:06:09Z","timestamp":1721606769000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05018-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5018"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05018-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"18 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"An opinion has been obtained from the Ethics Committee of Rhineland-Palatinate, Mainz, Germany, in accordance with the guidelines and recommendations for ensuring Good Epidemiological Practice (GEP). Due to the epidemiological nature of the study, no additional opinions from ethics committees were required. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The study was supported by unrestricted grants from Amgen GmbH to the AIO-Studien-gGmbH of the German Cancer Society, AIO-SUP-0116\/ass. The funding source did not have any access to the data and was not involved in data analysis or manuscript writing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Professor Link received research funding and honoraria, acted on speakers\u2019 bureau, and\/or consulted for Accord Healthcare, Amgen, Hexal-Sandoz-Novartis and TEVA Mr Kerkmann and Mrs Holtmann report payment from AIO-Studien-gGmbH, during the conduct of the study. Dr. Ohlmann reports personal fees from AMGEN, during the conduct of the study. Dr. Diel reports personal fees from Amgen, personal fees from Roche, personal fees from Hexal, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}